Three further versions of the model all without the APAS and results without the APAS were received by the ERG on 8th October. The ERG were requested to:
- check that the PAS has been removed appropriately
- check analyses where bevacizumab wastage is accounted for
- provide opinion on which are the most appropriate scenarios

Removal of APAS
This appears to have been implemented correctly.
The variable ████████████████████████████████ has been set to
███. The costs for bevacizumab no longer relate to the fixed price per cycle.

Appropriate scenario
As detailed in their report the ERG believe that the most appropriate scenario for consideration may be:
2x2 part of N016966 trial, patients with prior adjuvant therapy excluded, XELOX and FOLFOX arms unpooled.
In addition for calculations without the APAS it is important that bevacizumab drug wastage costs are included.

Presentation of results
The 95% percentiles for the ICERs are misleading. There are some negative ICERs which relate to simulations with small neg inc. QALYs. For example for scenario 6 the results presented are 130,281 (-231,910, 713,057), the ERG suggest that the results should be 130,281 (73,147, dominated). This is clearly demonstrated by viewing the CE scatterplot.

Including costs of drug wastage
The cost of oxaliplatin should always be adjusted for wastage (as requested by the ERG in clarification points). The cost of bevacizumab should be adjusted to include the cost of drug wastage if the APAS is not being applied.

The model has ████████████████████████████████ :
██
██

The dose including wastage is based on a patient weight of ████ kg.
At 5mg/kg   one 400mg vial
At 7.5mg/kg   one 400mg vial and two 100mg vials

A mean patient weight of ████████ is used which is stated to be from the N016966 trial. The ERG did not find this reported in the papers relating to the study. If a value for standard deviation of weight is available then this variable should also be included within the PSA.

The three models received by the ERG on 8th October:
'AVASTIN MCRC_NICE_2by2 ERG changes no APAS'
'AVASTIN MCRC_NICE_2by2 ERG changes excl Adjuvant no APAS'
'AVASTIN MCRC_NICE_+-P pooled ERG changes no APAS'

do not include oxaliplatin or bevacizumab drug wastage costs.

(The bevacizumab cost is calculated in cells ▮▮▮▮▮▮▮ but these values are not used in the model. Changing the value in ▮▮▮▮▮▮▮▮▮▮▮ does not change the costs to include/exclude wastage but it does change between actual/planned dose. Oxaliplatin number of vials used should be calculated in the ▮▮▮▮▮▮▮▮▮▮▮▮▮▮▮▮▮▮ but this has not been done.)

ERG analysis
Using the model 'AVASTIN MCRC_NICE_2by2 ERG changes no APAS' and modifying it to include bevacizumab and oxaliplatin drug wastage costs – (▮▮▮▮▮▮▮▮):

	ICERs	
	XELOX+bev vs. XELOX	FOLFOX+bev vs. FOLFOX
Presented by manufacturer	£90,779	£240,324
Calculated by ERG including ox and bev wastage	£100,128	£264,328

Using the model 'AVASTIN MCRC_NICE_2by2 ERG changes excl Adjuvant no APAS' and modifying it to include bevacizumab and oxaliplatin drug wastage costs:

	ICERs	
	XELOX+bev vs. XELOX	FOLFOX+bev vs. FOLFOX
Presented by manufacturer	£92,698	£96,687
Calculated by ERG excluding ox and bev wastage (unclear why different to row above)	£92,702	£96,691
Calculated by ERG including ox and bev wastage	£102,276	£105,944